Intec Pharma

Controlled Drug-delivery Technology for the Upper Gastrointestinal Tract

Health Tech & Life Sciences
Non Active, Aug 2021 ceased to operate

Company Overview

Snapshot

Founded in October 2000 by Zvi Joseph, Intec Pharma is a biopharmaceutical company with 1–10 employees. The company has raised a total of $80.4 million across 5 funding rounds from 5 investors. In August 2021, Intec Pharma was delisted from NASDAQ and TASE due to its acquisition by Decoy Biosystems.

Business overview

Intec Pharma is a clinical-stage biopharmaceutical company specializing in developing drugs using its proprietary Accordion Pill (AP) platform technology. This oral drug-delivery system is designed to enhance the efficacy and safety of both existing and developmental drugs through efficient gastric retention and specific release mechanisms. The company's pipeline includes Accordion Pill Carbidopa/Levodopa for Parkinson's disease and AP-cannabinoids for various indications, including cancer pain and opioid-sparing pain management. Intec Pharma operates within the Health Tech & Life Sciences sector, focusing on pharmaceuticals and drug delivery.

Strategic signal

In August 2021, Intec Pharma closed a merger with Decoy Biosystems, leading to its delisting from NASDAQ and TASE. This strategic move indicates a significant shift in the company's operational structure and future direction, signaling to investors a pivot towards integration within a larger entity and a potential re-evaluation of its drug development focus under new ownership.

Company Intelligence Q&A

What is Intec Pharma's core technology?
Intec Pharma's core technology is the proprietary Accordion Pill (AP) platform, an oral drug-delivery system designed to improve drug efficacy and safety through efficient gastric retention and specific release mechanisms.
When was Intec Pharma founded and by whom?
Intec Pharma was founded in October 2000 by Zvi Joseph.
What was a significant corporate event for Intec Pharma in 2021?
In August 2021, Intec Pharma closed a merger with Decoy Biosystems, which resulted in its delisting from NASDAQ and TASE.
What was the outcome of Intec Pharma's Parkinson's trial in July 2019?
In July 2019, Intec Pharma's Parkinson's trial experienced a failure, which led to a significant drop in its stock value.
Did Intec Pharma announce any research collaborations in 2019?
Yes, in May 2019, Intec Pharma announced a research collaboration agreement with Merck.

External links